Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor-Reference-Cited by-同舟云学术

Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor

Published:2007-07-01 Issue:7 Volume:30 Page:1862-1864
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Bergman Arthur J.¹,Cote Josee¹,Yi Bingming¹,Marbury Thomas²,Swan Suzanne K.³,Smith William⁴,Gottesdiener Keith¹,Wagner John¹,Herman Gary A.¹

Affiliation:

1. Merck Research Laboratories, West Point, Pennsylvania

2. Orlando Clinical Research Center, Orlando, Florida

3. DaVita Clinical Research, Hennepin County Medical Center, Minneapolis, Minnesota

4. New Orleans Center for Clinical Research, Knoxville, Tennessee

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/30/7/1862/597139/zdc00707001862.pdf

Reference6 articles.

1. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE: (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyra-zin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)-butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141–151, 2005

2. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Chen L, Zeng W, Musson D, Laethem M, Zhou YY, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA: Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharm Therap 78:675–688, 2005

3. Zeng W, Wang AQ, Fisher A: L., Musson DG: Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. Rapid Commun Mass Spectrom 20:1169–1175, 2006

4. Rowland M, Tozer T: Appendix I: Additional concepts and derivations. In Clinical Pharmacokinetics: Concepts and Applications. Baltimore, MD, Williams & Wilkins, 1995, p. 469–506

5. Bergman AJ, Stevens C, Zhou YY, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28:55–72, 2006

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease;Endocrinology and Metabolism;2024-08-31

2. Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report;Journal of Pharmaceutical Health Care and Sciences;2023-12-11

3. Pharmacokinetics and relative bioavailability of sitagliptin hydrochloride and sitagliptin phosphate tablets formulations: a randomized, open-label, crossover study in healthy male volunteers;Generics and Biosimilars Initiative Journal;2023-04-15

4. Ultrasensitive Chemically Modified Carbon Paste Sensor for Reliable and Selective Potentiometric Determination of Trace Amounts of Sitagliptin in Real Samples;ChemistrySelect;2022-08-03

5. Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units;Medicina;2021-12-17